AllianceBernstein’s Major Healthcare Stock Changes in $10 Billion Sector Portfolio

Wall St. Watchdog reveals information regarding AllianceBernstein’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 316 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $9.94 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, AllianceBernstein reported holding 28,677,604 shares with a market value of $1,907,634,122. This comprised 1.68% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 24,573,097 shares with a market value of $1,565,060,514. This comprised 1.82% of the total portfolio. The net change in shares for this position over the two quarters is -4,104,507. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, AllianceBernstein reported holding 25,744,983 shares with a market value of $1,066,099,742. This comprised 0.94% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 30,661,762 shares with a market value of $1,189,676,342. This comprised 1.38% of the total portfolio. The net change in shares for this position over the two quarters is 4,916,779. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Wellpoint Inc. (NYSE:WLP): On 06/30/2011, AllianceBernstein reported holding 13,790,798 shares with a market value of $1,086,301,112. This comprised 0.96% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 14,626,607 shares with a market value of $954,824,887. This comprised 1.11% of the total portfolio. The net change in shares for this position over the two quarters is 835,809. About Company: WellPoint Inc. is a health benefits company. The Company provides health benefits, dental and vision benefits, pharmacy benefits, life insurance, and life and disability insurance benefits. WellPoint operations include Blue Cross and Blue Shield plans.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, AllianceBernstein reported holding 13,878,704 shares with a market value of $715,863,578. This comprised 0.63% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 18,345,019 shares with a market value of $846,072,257. This comprised 0.98% of the total portfolio. The net change in shares for this position over the two quarters is 4,466,315. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Astrazeneca Plc (NYSE:AZN): On 06/30/2011, AllianceBernstein reported holding 14,781,953 shares with a market value of $740,132,382. This comprised 0.65% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 13,729,170 shares with a market value of $609,025,990. This comprised 0.71% of the total portfolio. The net change in shares for this position over the two quarters is -1,052,783. About Company: AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.
  • Allergan Inc. (NYSE:AGN): On 06/30/2011, AllianceBernstein reported holding 7,527,134 shares with a market value of $626,633,906. This comprised 0.55% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 6,876,371 shares with a market value of $566,475,424. This comprised 0.66% of the total portfolio. The net change in shares for this position over the two quarters is -650,763. About Company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, AllianceBernstein reported holding 12,640,399 shares with a market value of $446,079,692. This comprised 0.39% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 12,318,235 shares with a market value of $402,806,294. This comprised 0.47% of the total portfolio. The net change in shares for this position over the two quarters is -322,164. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, AllianceBernstein reported holding 7,878,421 shares with a market value of $475,226,352. This comprised 0.42% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 6,315,383 shares with a market value of $390,985,361. This comprised 0.45% of the total portfolio. The net change in shares for this position over the two quarters is -1,563,038. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Covidien Plc (NYSE:COV): On 06/30/2011, AllianceBernstein reported holding 4,903,786 shares with a market value of $261,028,527. This comprised 0.23% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 6,868,430 shares with a market value of $302,897,753. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is 1,964,644. About Company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, AllianceBernstein reported holding 5,785,093 shares with a market value of $337,560,168. This comprised 0.3% of the total portfolio. On 09/30/2011, AllianceBernstein reported holding 5,334,558 shares with a market value of $293,187,303. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is -450,535. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.

(Note: Data regarding AllianceBernstein’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet